RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...